39.65
+1.45(+3.80%)
Currency In USD
| Previous Close | 38.2 |
| Open | 38 |
| Day High | 39.78 |
| Day Low | 36.31 |
| 52-Week High | 40.96 |
| 52-Week Low | 12.21 |
| Volume | 368,982 |
| Average Volume | 513,262 |
| Market Cap | 1.1B |
| PE | -14.06 |
| EPS | -2.82 |
| Moving Average 50 Days | 28.81 |
| Moving Average 200 Days | 22.55 |
| Change | 1.45 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $2,332.35 as of November 09, 2025 at a share price of $39.65. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,338.62 as of November 09, 2025 at a share price of $39.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Participation in November Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 9:15 PM GMT
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
GlobeNewswire Inc.
Oct 29, 2025 1:15 PM GMT
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm durable clinica
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
GlobeNewswire Inc.
Oct 13, 2025 1:15 PM GMT
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab,